GlassScriptPhysician profile
Edward L Friedland
NPI 1649273327
$2,817.84
in general payments reported to CMS, 2019-2025
28 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $113 · 2021: $64.53 · 2022: $186 · 2023: $495 · 2024: $923 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,953 · Education: $35.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.15 |
| Education | $35.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $446.45 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $376.79 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $356.72 | 2019-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $157.47 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $152.72 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $141.57 | 2024-2025 | |
| Travere Therapeutics, INC. | $121.13 | 2024-2025 | |
| Amgen INC. | $119.81 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Bard Peripheral Vascular, INC. | $96.79 | 2019 | |
| Ardelyx, INC. | $96.01 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $89.01 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $81.33 | 2022-2024 | Tarpeyo |
| Akebia Therapeutics INC | $78.19 | 2019-2024 | Auryxia, Vafseo |
| Vifor Pharma, INC. | $74.46 | 2019-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $73.77 | 2025 | Ultomiris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $62.62 | 2019-2024 | Velphoro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.26 | 2019-2025 | Voyxact |
| Apellis Pharmaceuticals, INC. | $39.94 | 2025 | Empaveli |
| Lilly USA, LLC | $39.41 | 2024 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $25.04 | 2019-2020 | |
| Medtronic, INC. | $20.82 | 2021 | |
| Chiesi USA, INC. | $19.82 | 2024 | Cleviprex |
| Glaxosmithkline, LLC. | $16.14 | 2023 | Benlysta |
| Ascendis Pharma Endocrinology INC | $15.69 | 2025 | Yorvipath |
| Alnylam Pharmaceuticals INC. | $15.34 | 2023 | Givlaari |
| Genzyme Corporation | $15.29 | 2023 | |
| Mallinckrodt Enterprises LLC | $14.08 | 2019 | |
| Hologic Sales and Service, LLC | $13.17 | 2024 | Novasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Friedland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.